No More Hypoglycaemia On Days With Physical Activity And Unrestricted Diet When Using A Closed-Loop System For 12 Weeks: A Post Hoc Secondary Analysis Of The Multicentre, Randomized Controlled Diabeloop Wp7 Trial

A post hoc analysis of the Diabeloop WP7 multicentre, randomized controlled trial was performed to investigate the efficacy of the Diabeloop Generation-1 (DBLG1) closed-loop system in controlling the hypoglycaemia induced by physical activity (PA) in real-life conditions. Glycaemic outcomes were compared between days with and without PA in 56 patients with type 1 diabetes (T1D) using DBLG1 for 12 weeks. After the patient announces a PA, DBLG1 reduces insulin delivery and, if necessary, calculates the amount of preventive carbohydrates (CHO). Daily time spent in the interstitial glucose range less than 70 mg/dL was not significantly different between days with and without PA (2.0% +/- 1.5% vs. 2.2% +/- 1.1%), regardless of the intensity or duration of the PA. Preventive CHO intake recommended by the system was significantly higher in days with PA (41.1 +/- 35.5 vs. 21.8 +/- 28.5 g/day; P < .0001), and insulin delivery was significantly lower (31.5 +/- 10.5 vs. 34.0 +/- 10.5 U/day; P < .0001). The time spent in hyperglycaemia and the glycaemic variation coefficient increased significantly on days with PA. In real-life conditions, the use of DBLG1 avoids PA-induced hypoglycaemia. Insulin adjustments and preventive CHO recommendation may explain this therapeutic benefit.